Candida in the ICU, Risk Management and Patient Safety

Endogenous candidiasis remains an underrecognized yet clinically relevant complication in non-neutropenic critically ill patients. This study examines Candida spp. infections in the intensive care unit (ICU) within a patient-safety and risk-management framework, focusing on the identification of patients at highest risk and the development of an early diagnostic and therapeutic strategy. The target population comprises long-stay ICU patients requiring prolonged mechanical ventilation who develop multiple organ dysfunction syndrome (MODS) associated with immunoparalysis, typically reflected by a Sequential Organ Failure Assessment (SOFA) score ≥ 5. In this population, Candida spp. colonization may evolve into multifocal candidiasis and subsequently invasive or disseminated disease. Notably, candidemia often represents a late manifestation and therefore lacks sensitivity as an early diagnostic marker. Drawing on a series of clinical investigations conducted from 1978 to the early 2000s, the authors developed a standardized diagnostic–therapeutic algorithm based on systematic surveillance cultures, identification of multifocal Candida spp. colonization, and early initiation of antifungal therapy. Implementation of this strategy, together with progressive individualization of antifungal treatment, was associated with a marked reduction in attributable mortality related to candidiasis in ICU patients. These findings support the concept of Candida spp. infection as a sentinel indicator of systemic immune dysfunction and physiological fragility in critical illness. Integrating risk-based surveillance with early targeted therapy may substantially improve outcomes and reinforce patient-safety strategies in the ICU.